Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Wellness and prevention of illness)

Innovation 'Elevator Pitch':
Liva Healthcare can reverse chronic lifestyle diseases, such as Type 2 Diabetes through digital lifestyle coaching. Liva is a hybrid model of technology and human intervention that drives long term behaviour and lifestyle changes
Overview of Innovation:
 
Founded in 2014, Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management.  
  
Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England, AXA PPP Healthcare and Copenhagen Municipality.  
  
Liva Healthcare’s platform facilitates ongoing personalised health coaching through an intuitive app, building strong bond between coach, GP and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity and heart disease, by driving behaviour change.   
   
Currently being used in Denmark, UK and Sweden, the app is multilingual across several languages. It has proven to work efficiently across all socio-economic backgrounds and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviours stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes.  
  
Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform, or as a turn-key solution, dependent on client specifications.  
  
Liva Healthcare has offices in Copenhagen, Denmark and London, UK. 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
By helping to both prevent and cure chronic lifestyle diseases, Liva consequently relieves the cost pressures on healthcare systems.  Unhealthy lifestyles lead to significant cost pressures on healthcare systems. For example, in the UK it is claimed that Type 2 diabetes costs the National Health Service (NHS) £8.8 billion per year, which equates to almost 9pc of its annual budget and causes 20,000 early deaths per year. In addition, it is estimated that obesity costs the NHS over £5 billion per year.   
 
The platform also allows health professionals to monitor up to 400 patients at the same time. This enables the NHS to save costs as the digital health tool can help patients come off medication. It also drives efficiency by enabling more patients to be monitored.  
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The primary benefit that Liva Healthcare provides patients with is the opportunity make long-term lifestyle changes to diet and exercise, with the help of a personal health coach, that can prevent or remove their lifestyle disease (e.g. Type 2 diabetes, obesity or heart disease).  
 
Liva was designed to help prevent and reverse chronic diseases caused by unhealthy modern lifestyles, such as Type 2 diabetes and heart disease, both of which are often caused and affected by weight gain. The app is based on clinical research that has shown lifestyle interventions can lead to long-term lifestyle change and help patients reduce their risk of the disease or enter remission by losing weight.  
 
For example, Liva Healthcare monitored the progress of 136 patients using its digital healthcare app to prevent and roll back Type 2 diabetes over a nine-month period. Over the period, 82% of the patients (112) lost weight, losing an average of 6.3kg, demonstrating signs of a successful lifestyle intervention.  
Current and planned activity: 
In response to the crisis the NHS chose Liva as one of five providers to tackle Type 2 diabetes using digital innovations. GPs can now refer patients at risk of Type 2 diabetes in North East London, Humber, Coast and Vale to use the Liva app. Patients are given a personal health coach and an app to help monitor and track their health goals. The app is based on strong evidence that has shown lifestyle interventions, delivered digitally, can lead to long term lifestyle change and help patients with, or at risk of, Type 2 diabetes reduce their risk of the disease or enter remission. Liva holds the firm belief that prevention is better than cure. Though, in many instances, its platform has been proven to facilitate both. 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Simon Pickup 01/10/2018 - 14:47 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Teleswallowing enables poorly people to be seen more rapidly by specialists and improves staff productivity threefold
Overview of Innovation:
Teleswallowing is an approach using technology whereby a speech and language therapist can run a virtual clinic to triage, manage and review his/her patients with eating and drinking problems (dysphagia).  Teleswallowing Ltd staff train the carers within residential and care settings to be able to link remotely with speech therapists to provide rapid access to specialist skills to avoid unnecessary distress, avoidable deterioration and hospital admissions.  Speech and Language Therapy is a scarce resource and the waiting lists to see a specialist are long.  The use of Teleswallowing technology prevents vulnerable people suffering and can be used as an out of hours/weekend cover approach. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption
Benefit to NHS:
I developed the approach at Blackpool where it is used; NWAHSN sponsored its development in Cheshire and West Hants CCG has commissioned the use in Southampton.  We have proven, through clinical trials supervised by Dr Liz Boaden from the University of Central Lancashire, that the approach increases staff productivity three fold and saves approximately £60 per assessment.  University College London used the approach in a workforce scoping project and found that 10.38 weeks of speech therapy time could be saved by using Teleswallowing.  Please see all evaluations on www.teleswallowing.com
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Many SLTs (speech and language therapists) are women working part time and below their level of training due to having child care or elderly parent responsibilities.  We would like to upscale our approach so that we not only offer training in the approach, but are able to deliver commissions for weekend/out of hours cover remotely, giving the opportunity for West Midland SLTs to work from home at hours best suited to their life and also help reduce the waiting times for sick people needing dysphagia assessments.  The SLTs would earn a better income, use their hard earned skills and be of benefit to the health system - by utilising a modern, digital approach.
Current and planned activity: 
The approach is used at Blackpool Teaching Hospitals, Cheshire and West Hampshire CCG.  I am bidding for a Women in Innovation award (Innovate UK) in order to develop the approach into an e-learning package, an app which then will be a digital clinic portal whereby SLTs will book in their availability to fulfil contracts remotely.  The SLTs will also be able to take advantage of the e-learning videos/second opinions/webinars which I intend to develop if I win the funding which goes with the Women in Innovation bid.
What is the intellectual property status of your innovation?:
Teleswallowing Ltd is a limited company and we have registered the name as ours.  The intellectual property is ours.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Veronica Southern 09/09/2018 - 15:59 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
People living with dysphagia - swallowing difficulty - need drinks that flow slowly.
We are to help them make Slõ Drinks for all their healthcare needs.
Overview of Innovation:
For people with dysphagia, ordinary drinks like you and I have flow to fast for them to cope with.
As a result they choke when they drink, which can lead to aspiration pneumonia, malnutrition and readmission.

To prevent this they must make all their drinks flow slowly and at specific speeds. This is done by adding thickener using a scoop. However, it is very difficult to add the right amount with a scoop and make every drinks safe to swallow.

We have therefore taken all the drinks someone could need or want, calculated the amount required and put that in a sachet. Then sachet contents are simply mixed with the volume of liquid we specify to change drinks for hydration into Slõ Juice, Slõ Tea or Slõ Fizzy. Drinks for medication such as soluble laxatives into Slõ Solulax and drinks for relaxing with into Slõ Wine, Slõ Beer and Slõ Cider.

Oral Nutritional Supplements (ONS) are different.
 
Powdered and ready to drink ONS are difficult to impossible to thicken safely with starch and gum thickeners. Consequently, health care professionals prefer to reduce risks by prescribing Fresubin and Nutilis Complete pre-thickened ready-to-drink ONS.
 
They cost £2.20 each and the NHS spent £4,500,000 on them over the last year.
 
The innovation I want to introduce to your CCG's is an alternative which provide all the safety of a ready to drink ONS for the price of a powdered one. Called Slõ Milkshakes+ they are the 1st pre-thickened and powdered protein rich ONS on prescription.

Costing 84p each, they provide a saving per prescription of £ 80+ per month or £ 900+ per patient
per year. If Slõ Milkshakes+ were used during the same period they would have saved a massive
£ 2,800,000.

They also provide huge environmental savings. Slõ Milkshakes+ are presented in powder form in sachets. Not using single use plastic bottles, dramatically reduces the CO2 impact of manufacture, delivery and recycling. Our sachets can even be incinerated and used in energy recovery plan.
 
Just as importantly, Slõ Milkshakes+ are drinkable. Made with whole milk from the fridge, they taste fresh, do not taste too sweet or have a metallic aftertaste. Ultimately, that makes it easier gain compliance and maintain patient’s oral nutritional intake.
 
It’s for all these reasons they are being added to Formularies across the UK and why I want to introduce Slõ Milkshakes+ with the aim of introducing your CCG’s to
Slõ Milkshakes+.
 
There is additional useful information here: www.slodrinks.com/ons



 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Innovation and adoption / Person centred care
Benefit to NHS:
Slõ Milkshakes+ have been created to help reduce financial and environmental costs whilst improving patient outcomes - now and in the future.

Just focusing on costs - as previously stated, Slõ Milkshakes+ save £80.00+ per prescription. That may not seem like a huge amount, but the cumulative saving is huge.
 
From March 2017 to March 2018, the NHS spent £ 4,500,000 on Fresubin and Nutilis Pre-thickened ready to drink ONS. In comparison to spend on medications that is not a lot. However, spend on products for dysphagia is going to increase for two key reasons.
 
Firstly, healthcare professionals are not seeking to diagnose dysphagia. As recently as two months ago the Doctors dedicated website www.gponline.com made identifying Dysphagia a Red Flag topic.
The reason – they now recognise the impact dysphagia has on treating the primary condition.
 
If a patient is diagnosed with it every medication, drink and supplement has to be altered so it can be swallowed safely without inducing aspiration.
 
Secondly, it is a secondary symptom of 127 conditions including; Stroke, Alzheimer’s, Head and Neck Cancer and Motor Neurone Disease. These conditions present themselves typically in the elderly and dysphagia affects 10-12% of those over 50 – an increasingly large proportion of our population.   
 
We can therefore predict with certainty, if the spend on ready-to-drink Fresubin and Nutilis just remains the same the accumulative spend in 5 years will be £ 22,500,000.
 
By making Slõ Milkshakes+ a 1st line response for dysphagia now over the same period the cost of prescribing Slõ Milkshakes+ would only be £ 8,148,000, saving £ 14,352,000!

 
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
Slõ Milkshakes+ make a positive impact to the health and wealth of the region through saving: saving patients from the risks of aspiration pneumonia, malnutrition and readmission; saving the CCG’s and healthcare professionals from unnecessary spend on expensive ONS for this patient group.
 
 
By providing a safe and reliable method to make safer to swallow ONS, Slõ Milkshakes+ reduce the risks of patients acquiring complications.
 
Patients will find it easy to consume the prescribed number of Slõ Milkshakes+ because they can actually drink them. They know they flow at the right speed and don’t need to worry about choking or embarrassing themselves in front of others – including their spouse.
 
When made Slõ Milkshakes+ look like ordinary milkshakes. No one can tell it flows slowly. It therefore doesn’t highlight their condition; gives them a feeling of inclusion.
 
Ultimately this makes for a better patient experience and improves compliance, which in turn saves them from the risks of malnutrition and re-admission.
 
Avoiding re-admission will save all the financial and patient costs associated with it, but and more importantly Slõ Milkshakes+ keep the costs of providing adequate nutrition in the Community to a minimum, saving CCG’s and healthcare professionals unnecessary spend on finances and time.
 
The financial savings are easy to quantify. Slõ Milkshakes+ will save £ 80+ per prescription every time a prescription is written for them instead of a ready to drink ONS.
 
Your CCG’s can quantify those savings by adding up the number of Fresubin and Nutilis Complete prescribed, multiplying by 84p (the Slõ Milkshake+ cost) and comparing the two.
 
Further savings are achieved by presenting Slõ Milkshakes+ in boxes of 7. A prescription can be written for just 7 sachets – a weeks’ supply – to see if a patient likes them. If they do, a larger prescription for one month’s supply can be written.
 
It’s also important to highlight the time saved, specifically time spent on implementation and training
in Nursing Home and Care Facilities where the majority of those with dysphagia reside.
 
These facilities typically have a high turnover of staff and many do not have English as a first language. As a direct result every Slõ Milkshake+ sachet features written and pictorial instructions to make sure they are always made correctly.
 
This makes training quick, easy and efficient, allowing health care professionals to focus on other important healthcare needs.
 
Current and planned activity: 
We are in constant contact with all divisions and levels of the NHS across the UK.
 
Our primary contacts have been healthcare professionals in Acute Hospitals, their colleagues in the Community and Doctors who have prescribed Slõ Milkshakes+.

During 2018 we have been focusing establishing relationships with CCG’s and their Medicines Management Team. We have been able to make contact via some Prescribing Support Dietitians but this has been difficult and slow.
 
This is why I have contacted all other ASHN's and yourselves - with a view to meeting your CCG’s and showing them how Slõ Milkshakes+ can help them and their patients.
What is the intellectual property status of your innovation?:
Our Competitors are giant Pharmacutical Companies and therefore a patent would be difficult to impossible to defend.
As a result I have had the Slõ Brand is trademarked here and in various Counties around the world.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Mathew Done 10/08/2018 - 10:17 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 15:11 Publish 5 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Catheters cause 250,000 serious infections, 3,000 deaths & up to £500m in healthcare costs a year research reports. UroShield prevents bacterial biofilm formation, increases antibiotic efficacy & decreases pain & discomfort of urinary catheter use.

Overview of Innovation:
90,000 Britons are fitted with a urinary catheter each year. Catheters are essential for a wide range of conditions that compromise the ability to empty the bladder effectively, such as prostate cancer patients and those with incontinence and neurological conditions like multiple sclerosis and spinal injury.
 
Indwelling catheters serve as an environment for bacterial attachment, biofilm formation and subsequent urinary tract infections (UTI). Biofilm formation is a thick, bacterial ‘glue’ that sticks to the surface of the catheter plastic and is highly resistant to antibiotics, making infections difficult to treat. Such catheter-acquired infections are one of the most common iatrogenic complications and may lead to increased mortality rates, extended hospital stays and increased medical costs for healthcare providers.
 
UroShield uses soundwaves to ‘shake’ away bacteria, protecting patients from painful and potentially life-threatening bladder infections. It is composed of 2 components: A disposable actuator which clips onto the external portion of the catheter and a portable battery powered driver.



The device sends out low-frequency ultrasound waves (Surface Acoustic Waves) which run longitudinally along both the inner and outer surfaces of the catheter. These surface acoustic waves prevent bacteria from docking and adhering to the catheter and subsequently prevent the formation of biofilm.
 
If there is a biofilm already present or one does form, the ultrasound waves help to break up the normally impenetrable biofilm matrix to allow access of the antibiotic to the biofilm. This increases the antibiotic efficacy by working synergistically so that patients may have a shorter course and lower dose of antibiotics.


In addition, independent studies from leading Universities have shown that the UroShield device enhances the immune systems’ ability to fight biofilm. In further studies the Uroshield device achieved a 90% reduction in the presence of common bacteria most likely to cause infection including E. coli and Staphylococcus epidermidis.
 
The action of the ultrasonic waves on the surfaces of the catheter interfere with the attachment of bacteria, prevents infections developing, reduces catheter encrustation and blockages and decreases or eliminates the need for antibiotics, reducing risk and improving patient outcomes. This in turn reduces the costs associated with indwelling catheter complications that may lead to increased medication and extended hospital stays.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Innovation and adoption
Benefit to NHS:
Reducing health care-associated infections (HCAIs) remains high on the Government’s
safety and quality agenda and in the general public’s expectations for quality of care.
 
Patients with invasive devices such as urinary catheters are at a greater risk of developing a HCAI (NICE, 2012). In addition to increased costs, each one of these infections means additional use of NHS resources, greater patient discomfort and a decrease in patient safety.
 
UroShield is a breakthrough device to prevent or treat catheter-related trauma.
 

 
Once the urinary catheter has been placed into the patient’s bladder, the actuator is clipped on the extracorporeal part of the catheter and the device is activated. UroShield harnesses the known therapeutic effects of ultrasound such as tissue healing and muscle relaxation to significantly decrease catheter-associated pain and discomfort. This is extremely easy for nurses to use and maintain, with a simple clip around the catheter to be changed monthly and disposed of in standard waste.
 
UroShield could have huge implications for reducing A&E admission rates as 224,670 admissions for UTIs were reported in 2009 and 2010 and since then numbers have continued to increase, with 43-56% of all UTIs being associated with indwelling. Between 2013/2014, the NHS spent £434 million treating 184,000 hospital admissions for a UTI.
 
UroShield could play a key role in achieving CQUIN targets for CAUTI rates and the reduction in E. coli Bloodstream Infections through the initial prevention of infection.
 
E. coli is one of the main pathogens responsible for causing UTIs and CAUTI, of which Gram-negative CAUTIs are often a source of bacteraemia. E. coli account for 55% of all BSIs and of these UTIs are responsible for 45% of E. coli BSIs. E. coli BSIs have increased by 20% over the last five years and the trend is still rising, which is of grave concern.
 
E. coli BSI are therefore a huge patient safety issue and are set to cost the NHS £2.3 billion by 2018. These contributed to over 5,500 NHS patient deaths in 2015 and there is £45 million quality premium which is incentivised by Ruth May to reduce healthcare associated Gram-negative BSIs by 50% across the NHS by 2021. The goals are to: prevent the need for antibacterial prescription, to reduce the dose or length or antibiotics as a minimum, and to reduce hospital admissions and HCAIs.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Over 1 million patients a year have a catheter for a short time while in hospital & those using them at home for longer periods have them changed every 3 months & infections can be missed between changes.
 
An untreated urinary tract infection (UTI) may spread to the kidney, causing more pain & illness & lead to sepsis, a life-threatening reaction to an infection.
 
Long-term catheterisation carries a significant risk of symptomatic UTI, which can lead to serious complications such as bloodstream infections (NICE 2012). The diagnosis of a CAUTI increases the use of antibiotics which will increase the burden & development of antimicrobial resistance (DH, 2007).
 
Recurrent lower UTIs have a detrimental effect on patients quality of life. Patients experience a psychological burden because they live with the anxiety of sudden acute episodes. The resulting social handicap is known to induce feelings of self-devaluation or culpability, which can lead to clinical symptoms of depression.
 
UroShield could protect thousands of patients from painful & potentially life-threatening bladder infections reducing the psychological burden & anxiety patients experience.
 
The innovation is currently being trialled in NHS hospitals with leading urologists including a consultant & surgeon at the Royal Marsden in London describing the device as ‘game-changing’.
 
Uroshield comprises an electronic driver (8-hour battery life) weighing 5g & a disposable clip that fits around the catheter tube, the driver transmits continuous ultrasound waves to the clip via a small cable. The rechargeable device can be switched on & off & a small screen on the driver indicates power supply & battery life.
 
Clinical trials have shown the acoustic sound waves generated by the UroShield device along the urinary catheter result in a significant decrease in catheter-associated pain & discomfort.
 
Click the image below to read the full article.


 
UroShield significantly reduces bladder washouts in catheterised patients & thus could reduce visits from district nurses to generate significant cost & time savings. For example, one patient required daily bladder washouts & since UroShield no longer requires any at all. Patients can have greatly extended catheter life, reducing the frequency of catheter change & maintenance & nurse callout time associated with this. Alongside freeing time & resources, UroShield could also assist Infection Prevention Nurses in achieving CQUIN targets based on catheter-associated infection rates.
Current and planned activity: 
We are speaking with over 80 primary and secondary care sites with regards to UroShield. We currently have 6 NHS sites evaluating UroShield in small scale patient service evaluations alongside a double-blind randomised controlled trial producing positive data proving the efficacy of UroShield.
 
We are also working to provide Health Economic Data which will further support the use of UroShield across various healthcare settings. To support this we are looking to work with a NHS partner in the West Midlands to undertake a small-scale (service) real-life evaluation of UroShield to demonstrate patient and fiscal benefits of using the device.
 
UroShield can help you to support the delivery of the national ‘reducing the impact of serious infections (Antimicrobial Resistance and Sepsis’ CQUIN by creating a new, improved pattern of care for patients, reducing their risk of painful and potentially life-threatening bladder infections.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Alex Ackernley 05/07/2018 - 08:41 Publish 4 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
This project uses art to inspire and inform, targeting geographical areas of social disadvantage where breastfeeding rates are low/ mothers may not have access to current research and may be unduly influenced by cultural barriers to breastfeeding.
Overview of Innovation:
Funded by ACE from 2017-18, the series of twenty-three photographic portraits of mothers breastfeeding by Lisa Creagh (Artist Practitioner) was animated into a film and exhibition-ready prints in January 2018. From January – May ‘Holding Time’ was shown at Fabrica Gallery, ONCA Gallery and Royal Brompton Hospital in London, in print, video and installation formats, accompanied by talks and workshops. ONCA featured a Breastfeeding Hub where comfortable seating encouraged mothers to stay longer and talk with other mothers. 
 
A dedicated website (www.the-parlour.org), was set up to broadcast interviews using Lisa Creagh’s YouTube channel. Here interviews by Lisa Creagh and Lucila Newell with participating mothers were posted as 5minute Podcasts. A Facebook promotion and postcard campaign drew visitors to the website, where a BLOG written by Sociologist Lucila Newell explored issues surrounding the cultural barriers to breastfeeding and an events page directed them to exhibitions and workshops/talks.  
 
Findings:
  1. Responses from audience at exhibitions was more mixed in gender and age than anticipated
  2. Workshops and talks were attended by more academic, medical and health researchers/practitioners than expected
  3. Online sharing of ‘Holding Time’ slideshow brought a large proportion of the audience to Podcasts 
  4. ‘The Parlour’ was not needed as a separate brand identity for the website: numbers of direct visitors were less significant than online sharing and YouTube recommendations. 
  5. The Breastfeeding Hub resulted in longer visits to exhibition
  6. Interviews/talks/workshops revealed structural barriers within health practice.
 
Figures (Jan-May 2018) 
 
Exhibitions x 10 days/ 435 visitors
Website: 1,000 users/ +67%
Talks x 2: 70 attendees
Facebook fans 303 posts/+91 fans/ +695 engagement
Instagram: +87 posts/+346 followers/ +1.4k engagement 
Twitter: 155 Tweets/+55 Followers/+25 engagements 
YouTube Analytics: 8,907 Views/ +6,710/60 Likes/+63 Subscribers
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Person centred care
Benefit to NHS:
There is a wide disparity between the emphasis on breastfeeding in culture and the support for mothers attempting to breastfeed for the first time. There are approximately 700,000 newborn babies in the UK each year. Of these, a high proportion will be to new mothers with no experience or understanding of breastfeeding. Much funding for Health Visitor run baby groups and drop-ins throughout the country have been cut in the past two years due to budget constraints, leading to increasing social isolation of new mothers. Young mothers in particular may not have ever encountered another breastfeeding mother, given that the last generation was largely encouraged to bottle-feed. 

Holding Time is a project designed to address inequality and lack of opportunity. We know from a huge body of evidence that breastfed babies have better short and long term physical and emotional health outcomes.[1]But drop out rates in breastfeeding are still perilously high. Currently young women from disadvantaged backgrounds have breastfeeding rates of less than 29%[2]. But until cultural attitudes towards breastfeeding change, it is unlikely that this will be improved. 
 
One of the greatest challenges new mothers face is overcoming the dominant negative attitude towards breastfeeding in public[3]. The Infant Feeding Survey 2010 shows that In Brighton, breastfeeding rates are higher than the national average, but these statistics hide inequalities. 

The nature of this work is discursive,opening dialogues around breastfeeding between not only women, but also genders and generations where arguably there can be wide disparities in opinion. 

Using social media, a local postcard campaign to GPs, and a YouTube channel, the project uses the exhibition in a local community space as an opportunity to engage and invite the public to engage in multiple ways.
 
[1]Department of Health. Breastfeeding and the NHS Priorities and Planning Framework 2003-2007 (modified February 2007). London: Department of Health. www.dh.gov.uk/  
[2]https://www.jfhc.co.uk/Who_wants_to_eat_in_a_toilet_20947.aspx: “The prevalence of initiation of breast-feeding varies between neighbourhoods from 28% to 80.6%.”
[3]45% of mothers reported that they felt uncomfortable breastfeeding in front of other people, and this was most acute in public places (43%) http://www.hscic.gov.uk/catalogue/PUB08694/Infant-Feeding-Survey-2010-Consolidated-Report.pdf
Benefit to WM population:
Looking at the Public Health England Statistical findings of 2017/18 Quarter 3: the latest data on breastfeeding prevalence at 6-8 weeks after birth, areas such as Stoke on Trent, Sandwell and Nottinghamshire have particularly low rates of breastfeeding (31.8%, 37.2% and 39.5% respectively) for example but again these statistics represent take up, which would drop considerably within a couple of months. Given that the WHO has recently defended its position of the benefits of breastfeeding for at least two years, the challenge is to inspire this minority of mothers who do take up breastfeeding to continue for longer and to inspire more mothers to try, particularly young women who seem to struggle with the public face of breastfeeding. 
Current and planned activity: 
Next Stage:
 
  • Stimulate and curate conversations around breastfeeding to the public 
  • Dr Debra Bick (Expert)/Lisa Creagh to approach medical and academic researchers in the field of breastfeeding for content and collaboration
  • Podcast interviews with medical researchers, Paediatricians, midwives and heath practitioners to inform and integrate research with opinion, capitalising on the wide reach of YouTube platform. 
  • BLOG to comprise of guest posts by medical researchers focusing on issues raised by women in workshops and interviews e.g. the struggle to feed in the early stages, the establishment of lactation, post partum care, expressing, breastfeeding in public, etc
  • Tour of Holding Time to locations across the UK with low breastfeeding rates, including Breastfeeding Hubs where possible/appropriate
  • Facebook/Instagram channels to promote the exhibitions and web content above 
  • Accessibility expanded through transcripts/closed caption subtitles 
What is the intellectual property status of your innovation?:
Copyright of all images is held by Lead Artist Lisa Creagh
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Lisa Creagh 15/06/2018 - 15:13 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
We work to reduce unplanned hospital admissions. Proactive Health Coaching helps patients to better control their health and thus reducing non-elective care. Engaged patients seek care at the right place, helping the NHS use its resources efficiently
Overview of Innovation:
Health Navigator is dedicated to improving patients’ lives through digitally supported health coaching at scale which is underpinned by robust scientific evidence.
 
Our forward strategy includes delivering an effortless patient experience and a focus on the development of a range of digitised services. To enable this, we are transforming the ways in which we deliver our services.

One of our services is Proactive Health Coaching (PHC). PHC is a telephone-based health management service that improves patient health and quality of life, while ensuring that healthcare resources are spent as efficiently as possible.
 
PHC provides non-medical patient support to help patients understand their chronic conditions, plan their care and navigate an often-complex healthcare system.
 
By identifying those likely to see future avoidable unplanned care, a coach is able to proactively support the patient. Support including helping to stabilise their condition, feel more confident in managing their conditions and navigating the often-complex health care system, thus reducing the risk of unplanned care.
 

 
Our model is evidence-based and grounded in scientific research, supported by several successful randomised trials. In summary PHC uses a patented combined approach of:

1) a complex risk predicting algorithm to forward predict on a daily basis, patients which are at high risk of a non-elective admissions
2) to then provide a programme of individualised care to those at high risk using our nurse led case management programme.

The unique combination of the two provides the outcomes summarised below.

The end goals are:

1) To improve patient outcomes and reduce healthcare utilisation
2) To deliver operational efficiencies across the whole health system by reducing demand and avoidable admissions
3) To deliver a significant cost saving

Our company has successfully delivered this service to over 33000 patients in Sweden where we also conducted a randomised control trial with 12000 patients which statistically showed a reduction in healthcare utilisation by 30-50%. These results were published in the EJEM in 2013 and 2015.

We are now conducting another RCT in the UK with The Nuffield Trust as the principal investigator to replicate the Swedish results. We have over 7 CCGS already working with us and two years’ worth of data is showing statistically significant reductions of 30% in non-elective admissions and 36% in A&E attendances in the intervention groups.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Innovation and adoption
Benefit to NHS:

The intervention is co-created and patient goal focused.
 
First we get to know the patient during a face-to-face meeting with a health coach where we review the challenges the patient faces, agree on some shared goals and make a plan for the future.
 
Over the next 6-9 months, the coach and patient have regular contact as the patient continues to make progress. Over time, the patient becomes more confident about managing their own condition and seeking the right care, at the right time.
 
By the end of their coaching program most patients feel confident to continue independently. By this time, the risk of seeking avoidable unplanned medical care has decreased significantly.
 
Proactive Health Coaching is being delivered together with various CCG partners in England and will be evaluated by the Nuffield Trust on a yearly basis.
 
By supporting patients with weekly coaching calls, the randomised control trial with NHS Vale and York CCG is already showing high levels of improved patient experience, a reduction in attendances at A&E and fewer admissions to hospital. Patients being supported by their health coaching intervention are also reporting more confidence in the management of their conditions.
 
From a recent NHS Confed case study (June 2017), results collated by NHS Vale of York CCG are currently being evaluated and published by the Nuffield Trust, an independent health charity. In this early assessment of the trial, this case study covers 183 patients, of which 121 patients have had the support of a health coach, has yielded savings per patient in the first year of the intervention of £1,034 less than the control group. This means that the service is already close to break-even in its first year, as it costs £1,200 per person for a two-year intervention.
 
Moreover, there are the associated operational benefits from taking activity out of the system. In particular, the intervention group has had 63% fewer non-elective admissions and 60% fewer A&E attendances. The number of bed days was 17% less than the control group. The results also provide evidence of relevance, spread and replicability, with the initiative being easy to replicate, even in financially challenged care economies.
 
Recent results show a statistical reduction of 30% and 36% in non-electives and A&E attendances respectively. Since 2010 the Proactive Health Coaching service has helped over 15,000 patients to achieve better health, with 90% reporting that their health coach has improved their quality of life.
 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Proactive Health Coaching helps increasingly stressed health care systems.
 
We know that receiving the right care, at the right time is crucial to effective care, but navigating a highly complex health care system can often leave patients feeling overwhelmed or under treated, leading to repeated unplanned hospital visits or admissions. The stress on the system is apparent within emergency departments in the UK that are under increasing pressure as visitor numbers continue to rise.
 
But reports show that a lot of the health care we provide is avoidable. What’s more, the vast majority of resources end up funnelling to a small number of people. Health Navigator provides an evidence-based solution through non-medical, intensive, short-term coaching for patients with diverse and often complex health needs. Coaching results in reduced costs for this care heavy group and frees up much needed acute resources.
 
At Health Navigator, we have experienced nurses and AHPS working as health coaches who provide the support needed to understand health conditions, plan care, and enable patients to become more confident in managing their individual health needs.
 

 
The intervention is delivered in four phases.
 
Patient Identification: Identification through a predictive model to ensure the right intervention, to the right patients, at the right time.
 
Intervention: Non-clinical telephone-based intervention to empower the patient and improve ordinary care – so that avoidable care can be proactively prevented.
 
Evaluation / Monitoring: Continuous monitoring to ensure resource-efficient effort per patient.
 
Discharge: When patient is no longer in need of support a decision is jointly taken by patient and health coach to end contact.
 
Personal Health Coaching has the ability to significantly reduce avoidable healthcare consumption in the West Midlands, reducing costs and freeing up much needed acute resources. Latest results show a statistical reduction of 30% and 36% in non-electives and A&E attendances respectively. If scaled up across the West Midlands this could significantly reduce health inequalities, improve patient outcomes, reduce operational pressures whilst delivering a financial saving.
 
We are currently working with 3 CCG’s in the region and are seeking additional sites in the West Midlands to join our randomised control trial.

Current and planned activity: 
This is an exciting time for Health Navigator UK. We are encouraged by the progress we are making and are delighted to have secured a number of significant contracts to deliver new and innovative healthcare services in the UK.
 
Proactive Health Coaching is being delivered together with seven CCG partners in England and will be evaluated by the Nuffield Trust on a yearly basis. We are currently showing statistically significant reductions in the intervention group compared to the control of 30% in non electives and 36% in A&E attendances.
 
We are at the start of a significant growth phase but acknowledge we cannot do it alone and we are seeking additional sites in the West Midlands to work with.
 
If you would like to explore this opportunity please get in touch.
What is the intellectual property status of your innovation?:
Held by Health Navigator UK Ltd
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Ravinder Sandhu 21/05/2018 - 10:52 Publish 1 comment
4.3
3
Votes
-99999
Innovation 'Elevator Pitch':
We're developing an Autonomous Patient Observation System (APOS) which will automate patient observation in any environment.
Overview of Innovation:
We're a start-up creating an Autonomous Patient Observation System (APOS) which collects user data from facial expressions, physical activities, gait analysis, user habbits, agression and agitation, and so on. We're looking to provide a fully autonomous device which can gather all that data and generate reports, insights, classifications and statistical analysis.
The APOS device is the size of a can of beer, and is extremely easy to use; just register the patient, and let it work for as long as you need to. It does not use cameras, but only lazer depth sensors, and the final product will be low-cost. The APOS device aims to provide impartial, aggregated meta-data and insights, in order to make assessments and evaluations simpler, faster and more accurate.
We're focusing on a Dementia Observation System, and are also interested in frailty indexing. We will be releasing the beta product end of September, and if you would like to test one for free, please contact us.

You may find more information on our website: https://www.mechion.com
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
  • cost reduction because less workforce is needed to monitor and observe patients
  • time reduction because the task of observing and monitoring becomes automated
  • better quality of service: assessments become more accurate and decions more informed due to big data acquisition
  • product could potentially be used in homes, thereby reducing the need of placing patients in facilities
  • earlier diagnosis could be possible, remote diagnosistics and low-cost observation regardless of facilities
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
  • better quality of service received, since more data is collected on a 24/7 basis
  • reduction of costs will allow care-workers and nurses to focus on more important tasks, thereby helping the patients more
  • better and earlier diagnostics can potentially help patients sooner
  • patients could avoid hospitalisation, and be monitored from home
Current and planned activity: 
We are currently engaging international organisations (research clinics and Universities) but are looking for early adopters in the Midlands. We have interviewed and identified key problems and issues we can solve with machine learning and AI and are now moving into prototyping. We should have a beta product ready for testing end of September.
What is the intellectual property status of your innovation?:
Software and Hardware
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
4
Read more
Hide details
Alexandros Gkiokas 16/05/2018 - 12:50 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our web based visualisations of NHS datasets is disrupting the analytics market. It allows systems to understand cause and effect within their health economies and test hypothesis in real time by interacting with the data through drop down menus
Overview of Innovation:
Our vision is to give every NHS system leader in England a clear picture of the end to end journey for the populations they serve. At the same time we aim to save the NHS £millions by disrupting the market for low level analytics!
The challenge currently faced by all healthcare leaders is a lack of insight and meaningful, consistently-reported analysis regarding the position and performance of the healthcare system. This lack of insight hampers the efficacy of the strategic and operational planning process and the scope and effectiveness of monitoring and oversight.
This challenge sits in the context of masses of existing publicly available healthcare data. Data that’s time consuming for providers to prepare but underutilised due to its format, shape and local capacity and capability.
Our vision is to make VUIT.ONLINE, our information and insight portal, available across the entire NHS in England. The tools we’ve developed allow users to interrogate data across an provider, CCG, ST or ICS quickly and efficiently in a way which informs decision making and allows the impact of interventions to be validated using existing national datasets.
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
Our front-end combines different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through an online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses.The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource in the form of consulting and CSU costs which currently run into many millions.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
We do this in a pre-packaged but evolving, continuously-updated front-end combining different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through a scalable online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses at system level from the system’s own, current data within existing national datasets.
The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource. A fundamental success factor for the implementation of this innovation is a reduction in the cost of low-level analytical support to the NHS in the form of consulting and CSU costs which currently run into many millions.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
By giving system leaders the tools they require to effectively build end to end, whole system pathways and commission them outcomes will improve for the people of the West Midlands. However the way in which our innovation VUIT.Online is configured this benefit is freely available to all health economies in England
Current and planned activity: 
We are currently mid way theought the second wave of Test Bed applications where we are both an innovator and a defined test bed partner with a West Midlands CCG
What is the intellectual property status of your innovation?:
VUIT. Online and it's intellectual property is owned by its co-founders. It is built on licenced propriatry software and uses national data sets which exist in the public domain
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
VUIT. Online uses national data sets, propriatery analytcal software and globally recognised web developer frameworks (wordpress). As such it is scaleable across the entire NHS in England immediately
Measures:
Measurable outcomes:
-reduction in spend on low level analytics in the NHS in england
-reduction in patient pathway costs as health economies understand whole system costs more effectively and plan ICS's on this basis
-Improved ability to scale innovation in healthcare by giving innovators access to data which will support, clarify and stratify the way in which they develop and take their products to market
Adoption target:
We aim to make the resource available to all NHS managers in England through sharing examples of best practice around the use of VUIT.Online
Read more
Hide details
Adam Townsend 25/04/2018 - 14:31 Detailed Submission Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Raiing Medical manufactures non-invasive Connected Vital Signs Monitoring for essential clinical decision support, healthcare cost savings, and better quality of care through big-data analysis and AI technology for inpatients and outpatients.
Overview of Innovation:
Currently, the majority of patients in hospital have measurements of vital signs taken manually at 2 to 4 hour intervals, which means some irregular events on the patient may go undetected for hours, this will lead to serious consequences including additional treatment, re-admittance to intensive care units, or even death. On the other hand, the lack of qualified data after patients leave the hospital also increases the difficulties for doctors to identify a patients situation at home. 
 
Raiing Medical believes wearable and mobile technology will change this situation, therefore Raiing is pleased to announce that Raiing MPCMS solution is now available. Raiing MPCMS is a continuous multi-parameter central monitoring system with smart sensor interface and transceiver, which arms to better monitor patients’ vital signs and eventually improve patients’ safety. With the support of a wearable medical sensor and unique Raiing VitalCube, nurses/care givers could receive constant ECG, TEMP, Heart Rate, Respiratory Rate, Sp02 signals from multiple inpatients and alarm for irregular readings simultaneously into a central monitoring station or hospital IT system.  
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Person centred care
Benefit to NHS:
Raiing Wearable Vital Signs Monitors will cut down dramatically on Caregivers intervention, provide essential patient data for Hospital use, Home Caregivers use and Doctors Surgeries.  The net result is an increase in patient's quality of life,  significant reduction in readmissions to hospital and considerable savings to the NHS and beyond.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Our Wearable Monitors will allow for vital signs testing on the operating table, ICU, recovery in Hospital and uninterrupted monitoring in the home. Caregivers will pick up on fluctuations and administer assistance immediately saving readmissions to hospital or doctor intervention.
Current and planned activity: 
Our products are widely in use in China and the US.  We are now looking to introduce our products into the UK and Europe and are taking part in the Nightingale, Horizon 2000 project but have not yet had the chance to work with the UK NHS.
What is the intellectual property status of your innovation?:
Wholly OIwned by Raiing Medical Company, Beijing, China.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
John Sweeney 30/03/2018 - 12:29 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%.
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured. 

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy). 

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Lenght of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved. 

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for upto 7 days. Each patient recieves a new sensor and a reusable electronic device or Lobe. See how the system works @ 
https://www.youtube.com/watch?v=u6KB1hBPQbM​ 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Each year, there are approximately 500,000 admissions of Sepsis and Pneumonia with an average unit cost of £4,600 per admission. These two conditions are increasing in incidence and oftentimes lead to an escalation of care due to the risk of undetected deterioration. It is shown that a 5% reduction in the escalation of care of these two pathways alone, through the use of continuous Respiratory Rate monitoring triggering decreased time to interventions (Fluids, Oxygen, Antibiotics, Steroids), can reduce the average unit cost by £300 and the average length of stay by 0.5 days. This translates into a total Net cash saving of £115m and 250K bed days. Popular opinion suggests that as high as 20% reduction is achievable - Evidence pending. 

Each event prevented, having an average cost of £25,000, will pay for a whole year's supply of sensors for one year. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
West Midlands Trusts are driving the awareness of Sepsis through their ambulance services, patient awareness campaigns, and in-hospital initiatives. With 44,000 lives lost each year attributed to Sepsis, it is important to Prevent, Diagnosis Early, and Effectively Treat the condition. RespiraSense focused on the area of Diagnosis Early. Research suggests that NEWS2 is a more sensitive indicator of deterioration due to Sepsis than QSOFA. Both of which have Respiratory Rate as a key parameter to measure. There is clearly value in monitoring this essential vital sign accurately, and clear additional benefit to having it monitored continuously. RespiraSense achieves both with low impact of False alarm due to its innovative design, boasting advanced motion-tolerance. 
Current and planned activity: 
PMD Solutions is working with Nursing Times to launch an educational campaign on the clinical science and importance of respiratory rate monitoring in acute care clinical practice. 

In addition, PMD Solutions is looking for Respiratory and Emergency teams to partner with and create a culture of Peer Leadership in the development of best practice for respiratory rate monitoring. 
What is the intellectual property status of your innovation?:
RespiraSense is positioned to be the new industry standard in respiratory rate monitoring. It is patented in Europe, United States, China, Hong Kong, and Japan. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Myles Murray 02/03/2018 - 19:46 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Consultant Connect enables a GP to dial a single number to immediately reach an appropriate specialist.  Immediate Advice and Guidance is better for patients, clinicians & NHS. It is currently used in Elective, Urgent & Mental Health care settings.
Overview of Innovation:
Consultant Connect www.consultantconnect.org.uk is a simple CCG funded telecoms system that provides GPs with immediate access to telephone-based specialty mental health advice and guidance. By talking to a specialist, often whilst the patient is still in the surgery, the GP is better able to provide the right care first time to the patient, often avoiding an unnecessary referral or admission.  The specialist is based within a nearby NHS Trust Hospital.
 
GP calls connect directly, via a standard rate number, to teams of local specialists via their mobile phones with each specialist getting c 20 seconds to answer a call before it automatically forwards on to the next specialist. By connecting to teams of specialists, rather than to individuals, the connection rates are high.  The order in which specialists receive calls is based on a Rota of specialist availability that has been provided by the team. This rota can be either managed by us or by the team itself through an online portal.  The team of specialists are based in the local NHS Trusts.
 
Once connected, calls are recorded as highly encrypted, information-governed digital files which provide a medico-legal record which is available to the relevant GP practice and specialist team.  At the end of the call GPs are asked to stay on the line for a few seconds to rank the outcome – this gives the CCG a broad view as to the effectiveness of the system and their investment in it. Specialists are also asked to rank the outcome via text message as a back-up.
 
This service is in operation nationally across many specialties in physical and mental health.

In what instances should/can Consultant Connect be used?
The way in which this system is used is ultimately determined by the CCGs, Trust/Specialists and GP practices collectively, but it is generally accepted that calls will be made for patient-specific advice.
 
Within mental health we can connect GPs to the most appropriate mental health clinical professional (e.g. Psychiatrist, Psychologist, Cognitive Behavioural Therapist) to discuss issues such as:
  • Whether a referral is needed
  • Medication management/prescribing questions
  • Access to crisis support
We offer our service to best meet local needs between service users, GPs and Mental Health Trusts. 
 
We can tailor by service, specialty or pathway.
The speed of connection is such that the GP’s can (at their discretion) call whilst a patient is still with them.

Consultant Connect Service
https://www.youtube.com/watch?v=QWmNUubMCAE
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Why Trusts and CCGs work with us
  • Better patient experience – speeds up the care pathway, avoidance of unnecessary visits and contact with secondary care services, reductions in follow-up visits to GP Practices
  • Better GP experience – more patient episodes conclude with no follow-up work, case based learning, reconnecting with specialists
  • Better specialist experience – reduction in inappropriate referrals to secondary care services, reduction in the number of written requests for advice that require responses, reconnecting with GPs
  • Better for the mental health trust and CCG – full tracking of Advice & Guidance activity, greater ‘whole system’ efficiency, with savings available to support other hospital and community initiatives

How we perform
  • In Physical Health, across all elective care specialties, 66% of calls to Consultant Connect result in the patient avoiding a trip to hospital (referral or admission)
     
  • In Physical Health, across all of urgent care specialties, 27% of calls avoid a hospital trip that day (attendance or admission) and a further 36% of from A&E
     
  • In Mental Health, 39% of calls to our Mental Health Advice & Guidance line avoided a referral
 
What a Consultant Connect call has meant to …
… GPs
“The call enabled me to deal with some abnormal results in an efficient manner – which tests to request and what to do with the results. Saved a referral.”

… Consultants
“I took a call regarding a patient with syncope and ataxia. I avoided an unnecessary admission and got the lady seen urgently in an outpatient clinic.”

… Commissioners
“Consultant Connect is our only QIPP scheme that is over delivering against its YTD QIPP target. I’m genuinely struggling to know how to deal with all this positivity. It’s very unusual in my line of work. Great news.”
 
Testimonials:
https://www.youtube.com/watch?v=vEu7QDT4PzI
 
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
Nearly 2,000 patients were spared an avoidable visit to hospital in the West Midlands by GPs who used Consultant Connect to contact specialists for immediate advice.
 
Doctors in the West Midlands turned to Consultant Connect, which allows them to speak to a specialist, often with the patient still in the room and can save them waiting days for a response or being sent to hospital for further checks.
 
Around 1,850 patients were spared going to Sandwell Hospital as well as Heartland and Good Hope Hospitals in Birmingham.
 
The service covers cardiology, diabetes and endocrinology, gastroenterology, gynaecology, general surgery, haematology, paediatrics, renal medicine, urology and respiratory medicine.
 
Since the phone line launched, GPs from 100 surgeries across Walsall, Sandwell and Solihull have made nearly 2,500 calls to specialists to get expert advice on the best care for their patients.
 
Consultant Connect estimates that West Midlands GPs and consultants have saved the NHS £570,000 by ensuring patients get the right treatment from the beginning.
 
When local GPs used Consultant Connect, around 50 per cent of their patients avoided the inconvenience of a trip to hospital.
 
Ref: Pharmacy Choice, 9 June, 2017
https://www.pharmacychoice.com/news/article.cfm?Article_ID=1832970
In one West Midlands CCG, the number of outpatient referrals dropped by 6 per cent over a three-month period.   This was Solihull CCG into HEFT (Heart of England Foundation Trust). 
https://www.consultantconnect.org.uk/breaking-news-ccg-establishes-consultant-connect-responsible-for-6-dip-in-referrals

We are currently working with the following CCGs in the West Midlands AHSN area:
 
Solihull CCG, Coventry and Rugby CCG, South Warwickshire CCG, North Warwickshire CCG, Worcestershire (South Worcestershire CCG, Redditch and Bromsgrove CCG and Wyre Forest CCG).  We are also working with the GP Federation Modality Partners in Sandwell.
 
We are working with the following Trusts:
  • HEFT - Heart of England NHS FT
  • SWFT - South Warwickshire NHS FT
  • UHCW - University Hospitals Coventry and Warwickshire NHS Trust
  • WAHT - Worcester Acute Hospitals NHS Trust
  • Sandwell and West Birmingham Hospitals NHS Trust - SWBH
  • George Eliot Hospital (GEH)
Current and planned activity: 
Current activity:
We are delivering Consultant Connect with over 45 CCGs across the UK, covering more than 12.8 million patients and over 1,700 GP practices.  To date we have handled 98,000 calls.

Planned/Required activity:
We would like to further roll out Consultant Connect to willing GPs and Trusts.  We would also appreciate any assistance in undertaking a formal return on investment review of our service to show very clear and robust data that we save money, and quickly.
 
What is the intellectual property status of your innovation?:
Consultant Connect Ltd own the telecoms system software and BI data reporting.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jenny Welling-Palmer 15/02/2018 - 13:38 Publish 1 comment
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Digital Transfer bag for essential clinical patient information such as medical, falls and frailty information, diet/nutrition/hydration etc. To improve patient safety and provide important information to HCP's for patients conveyed.
Overview of Innovation:
Creation of a Digital Transfer bag for essential clinical patient information such as medical information, falls and frailty information, diet/nutrition/hydration etc. To improve patient safety and provide important information to Health Care Professionals for patients conveyed to Emergency Departments, hospital appointments or occupational therapy services. The app can also incorporate additional elements that will help to tailor their care such as an electronic falls risk assessment (eFRAT), simple initial questionnaires i.e. recent coughs and colds, general health, mental health, stability checks. Integration of Point of Care testing such as UTI testing for symptomatic patients. Results can be emailed to GP/ night nursing services for treatment prescription if required. Quick identification and treatment can improve patient experience and reduce falls risk associated with UTIs.
Stage of Development:
Ideas stage - Early concept and ideas stage
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Frail older people living in care homes are amongst the most vulnerable in our society.  Often simple referrals for outpatient clinics are aborted due to lack of sufficient information available and availability of knowledgable staff to accompany the patient.  Calls to paramedics result in conveyances for the same reason.
Within a care home when someone is conveyed to hospital they must be accompanied by a member of staff, this could be any one who is available, and they may not have a lot, if any, medical knowledge or knowledge of the persons previous health. Using an app would mean anyone would be able to travel to hospital with the patient as they would have all the information they would require on admission.
Currently personal and clinical information and standardised paperwork is being sent along with the patient in the ambulance. This opens up the possibility of sensitive data being lost, or not passed on to the care team who need it. The app would store encrypted data within the N3 network. Could utilise DM+D (Dictionary of medicines and devices) to reduce input error for medication information.
Ideally this could be operated in a phased approach with basic services initially and others added on in a second phase.
Care homes provide a vital service within the national health and care system, however due to insurance requirements many have become increasingly risk-adverse, insisting that the slightest stumble, confusion or change in a patient be medically reviewed.  With falls alone this results in calls to ambulance services that often result in unnecessary conveyance because the information is not routinely available.  Clinical, paramedic and patient time is wasted due to repeated appointments and attends due to insufficient information available at the point of incident.
 
Benefit to WM population:
Improved, faster treatment for illnesses, remote monitoring by qualified staff reducing need for appointments and long waiting times.  Nominated professionals and individuals can hold virtual consultations using shared information.
Current and planned activity: 
Early engagement and development has been discussed as part of an existing AHSN project in the East Midlands, but this area of work is not part of that project, and has been identified as an area of innovation and improvement.
A digital platform is already available and can quickly be tailored to deliver many of the requirements here, and this constitutes the current Phase of the work.
Next steps would be to engage with selected homes of both residential and nursing home categories and varying sizes to test performance, with the aim to roll out within a twelve month period.  
The following developments would be to work with other innovation partners to integrate with others digital technology platforms to support care homes in managing their patients, it would also be further developed to enable roll out in assisted living, sheltered housing and residential properties.
What is the intellectual property status of your innovation?:
This product is in development, and this is the first time we have shared it as we are now at the point of needing further advice and assistance.  WMAHSN have been approached to support us on protecting the IPR for this innovation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Andrea Baker 02/02/2018 - 19:13 Sign Posted 3 comments
0
0
Votes

Innovation 'Elevator Pitch':
Natural insulation to improve internal building air quality within both new build and refurbishment health properties.
Overview of Innovation:
Grenian are a specialist company offering natural insulation for both new buildings and refurbishment projects. Natural insulation is sourced from naturally occuring fibres such as sheep wool, hemp, wood and cellulose fibres. All of our insulation products are manufactured with harmless binders such as recycled polyester binders.
​In adiditon research has been published showing that natural insulation can help to improve building internal air quality such as reducing formaldehyde levels. We have supplied insulation on a number of health projects such as Maggies centre, Oldham. The centres offer support for patients suffering from cancer. In Germany research has been carried out showing that schools internal air environment improved by utilising sheep wool insulation in the internal building fabric.
​These examples confirm that natural insulation is a viable alternative to man made insualnts.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Clinical trials and evidence
Benefit to NHS:
Studies have shown that natural insulation can help to improve both existing and new building internal air quality. As a result patients potenitally will experience reduced respiratory ailments and conditions. Theoretically this would help to reduce cost burden of treatments for the NHS.
Initial Review Rating
2.20 (3 ratings)
Benefit to WM population:
Our innovation will potentially help to reduce patients respiratory conditions resulting in reduced illness and sickness. This would potentially help to increase productivity and reduce sick days.
Current and planned activity: 
We are not currently involved in direct communications with the NHS or other health authorities. However we have worked with national architects on health and well being projects where specification of suitable materials for the building fabric is a key factor within the design process.
What is the intellectual property status of your innovation?:
We supply materials from a variety of manufacturers who hold intellectual property on the various insulation products.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Rejection Reason:
Unable to contact Innovator to clarify aspects of submission.
Read more
Hide details
Matthew Nalborczyk 31/05/2017 - 13:26 Rejected 2 comments
0
0
Votes

Innovation 'Elevator Pitch':
Children are at risk of serious harm or even death because adults are mixing alcohol consumption with caring and parental responsibilitie. This campaign poses the question - "when parents drink, who's in charge?'
Overview of Innovation:
Parents from all backgrounds are putting their children at risk when they drink alcohol at home.

The 'Who's In Charge?' campaign from Birmingham Community Healthcare NHS Trust depicts real life child harm scenarios and asks – ‘when you drink, who’s in charge?’

The campaign was conceived in response to concerns that growing numbers of babies and children are at risk of serious harm because of the way their parents consume alcohol at home.

Safeguarding professionals warn that children are being placed in danger and even losing their lives because adults who in many cases do not consider themselves excessive drinkers are not exercising normal levels of care and attention while drinking or recovering from the after-effects of over-indulgence in alcohol.

And they warn of a ‘double jeopardy’ effect - that drinking too much alcohol can not only reduce a parent’s capacity to appropriately respond to children’s needs, but also make the drunken adult an active danger to the child.

One of the most worrying trends identified locally and nationally is a rise in the number of baby deaths connected with sleeping on a sofa with an adult who is under the influence of alcohol, the number of children left to care for their younger siblings and the impact of the example of parents’ drinking patterns on young people.

The number of victims of Sudden Infant Death Syndrome who were sleeping with a parent on a sofa has risen.

The campaign urges parents, and others with responsibility for children, to be aware of a range of potentially dangerous consequences if no adult remains sufficiently sober and aware of children’s needs or whereabouts.


In one year in Birmingham alone: 
  • 82% of babies who died from Sudden Infant Death Syndrome were sleeping with a parent at the time
  • 56% of these deaths were on a sofa; 44% in the parental bed.
  • 78% of the fatalities were associated with parental alcohol use at the time
  • while 44% involved parental drug use.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Education, training and future workforce / Person centred care
Benefit to NHS:
  • supportive of statutory safeguarding responsibilities through reduced risk of harm to children and young people
  • supportive of adult clinical services due to reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
  • marketing and education resources for professionals eg. health visitors, school nurses.
Initial Review Rating
3.60 (2 ratings)
Benefit to WM population:
  • reduced risk of harm to children and young
  • reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
Current and planned activity: 
A set of photographs has been commissioned depicting hard-hitting photographic case study scenarios based on real life evidence from serious case reviews and other reported incidents.

AVAILABLE TO OTHER TRUSTS FREE OF CHARGE - If you wish to use these in your organisation, please contact David Disley-Jones or MidTECH Innovations (www.midtech.org.uk).

A simple logo was designed and has been trade-mark protected with the IPO.
A set of posters has been produced which have been displayed in a variety of locations.
A set of aide memoire cards has been produced for use by professionals such as health visitors and school nurses to generate discussion and raise awareness.
Who's In Charge? has been licensed to British Armed Forces in Germany for use on military bases, in acknowledgement of the issue of alcoholic consumption among military families.

 
What is the intellectual property status of your innovation?:
The logo and the use of the phrase 'Who's in Charge?' (in certain contexts) has been trade-marked with the IPO.
The photographs are copyright BCHC/Roy Peters Photography.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
David Disley-Jones 30/05/2017 - 16:05 Publish Login or Register to post comments
0
0
Votes
-99999

Active Campaigns